Source: Healio News
Ciltacabtagene autoleucel induced a 95% overall response rate among patients with multiple myeloma who had early relapse after front-line therapy, according to results of a cohort analysis from the CARTITUDE-2 trial.
Data from the study — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — suggest the chimeric antigen receptor T-cell therapy is safe and effective when given as an earlier line of therapy for patients with high-risk multiple myeloma that does not respond to standard front-line treatments, researchers concluded.